bims-livmat Biomed News
on Living materials
Issue of 2026–11–08
four papers selected by
Sara Trujillo Muñoz, Leibniz-Institut für Neue Materialien



  1. bioRxiv. 2026 Oct 29. pii: 2026.10.27.761579. [Epub ahead of print]
      Engineered bacteria enable self-amplifying therapeutic delivery and immune activation, yet these same features drive systemic toxicity and off-target growth. Here, we create a "tumorobe" that overcomes these limitations by integrating reduced immunogenicity, tumour-restricted growth, and enhanced payload release. Specifically, we identify lipopolysaccharide modifications that reduce immunogenicity while preserving fitness, restrict growth to tumours using a hypoxia-lactate "AND" gate, and enhance extracellular payload release via lipoprotein deletion. This strain expands the maximum tolerated dose in a route-dependent manner by up to 1,000-fold. Across multiple murine models, including colorectal cancer and glioblastoma, the strain drives robust antitumour efficacy as both a standalone therapeutic and an immunotherapeutic delivery platform, achieving durable complete responses in up to 75% of colorectal tumours when armed with a cytokine payload. Together, these results establish a broadly applicable platform for safe and effective bacterial cancer therapy.
    DOI:  https://doi.org/10.64898/2026.10.27.761579
  2. Front Bioeng Biotechnol. 2026 ;14 1999112
      Bacteria and mammalian cells coexist and interact in many physiological and pathological environments, yet their direct in vitro co-culture is difficult because of mismatched growth rates, nutritional demands, and oxygen requirements. This Perspective discusses spatial engineering strategies that improve co-culture stability while preserving biologically relevant communication. We compare tumor spheroid colonization models, biomimetic hydrogel barriers, bacteria-containing microcapsules, layered hydrogel beads, and multiphasic droplets that support direct or indirect interactions. We further examine how material composition, crosslinking, pore size, shell thickness, mechanical stability, and compartment dimensions regulate bacterial confinement and molecular transport. Current systems still face trade-offs among leakage prevention, efficient exchange, physiological relevance, experimental duration, and throughput. Such models may enable mechanistic studies, therapeutic evaluation, and high-throughput investigation of dynamic bacteria-mammalian cell interactions under controlled conditions.
    Keywords:  bacteria; co-culture; hydrogels; microcapsules; spatial engineering
    DOI:  https://doi.org/10.3389/fbioe.2026.1999112
  3. Microbiol Immunol. 2026 Nov 02.
      Sepsis is a life-threatening condition characterized by dysregulated systemic inflammation and high mortality rates. Mesenchymal stem/stromal cells (MSCs) have emerged as promising immunomodulatory agents; however, genetic engineering strategies can enhance their therapeutic efficacy. This study evaluated the immunomodulatory and protective effects of MSCs genetically engineered to express leukemia inhibitory factor (MSC-LIF) in vitro and in a mouse model of lipopolysaccharide (LPS)-induced endotoxemia. In vitro, peritoneal macrophages stimulated with LPS + IFN-γ were co-cultured with MSC-LIF or wild-type MSCs (MSC-WT). MSC-LIF significantly reduced the production of TNF-α, IL-12, and nitric oxide compared with stimulated controls and demonstrated enhanced inhibition of IL-12 and nitrite levels relative to MSC-WT. Although IL-6 levels increased in co-cultures, MSC-LIF promoted a regulatory cytokine profile characterized by modulation of pro-inflammatory mediators. In vivo, C57BL/6 mice subjected to lethal endotoxemia with LPS were treated with MSC-LIF, MSC-WT, dexamethasone, or vehicle. MSC-LIF significantly improved survival in a dose-dependent manner, achieving 100% survival at the highest dose (1 × 106 cells), outperforming MSC-WT. Serum cytokine analysis revealed that MSC-LIF markedly reduced TNF-α, IL-6, IL-1β, and IL-12 levels while significantly increasing IL-10 production, indicating enhanced systemic immunoregulation. Collectively, these findings demonstrate that LIF expression potentiates the immunomodulatory and protective effects of MSCs in experimental endotoxemia. MSC-LIF therapy promotes a balanced inflammatory response and significantly improves survival, supporting its potential as a novel therapeutic strategy for severe systemic inflammatory conditions such as sepsis.
    Keywords:  endotoxemia; immunomodulation; inflammation; leukemia inhibitory factor; mesenchymal stromal cells; sepsis
    DOI:  https://doi.org/10.1111/1348-0421.70102
  4. iScience. 2026 Nov 20. 29(11): 118029
      Autonomous bioluminescence systems enable continuous light emission in engineered organisms by genetically encoding both luciferase enzymes and their substrate biosynthetic pathways, offering a powerful platform for non-invasive and long-term monitoring of biological processes. However, bioluminescence output is highly sensitive to substrate availability and host metabolic state, often leading to signal instability under energy-limited conditions. Here, we report an alternative luciferin biosynthetic strategy for the bacterial Lux bioluminescence system in which the adenosine triphosphate (ATP)-dependent LuxEC complex is replaced by α-dioxygenase (αDOX), an enzyme that directly converts fatty acids into fatty aldehydes without consuming ATP. Using machine learning-guided directed evolution, we engineered αDOX variants that markedly enhanced bioluminescence intensity when coupled with bacterial luciferase. The resulting ATP-free Lux bioluminescence system enabled single-cell-level bioluminescence imaging and showed a smaller reduction in light emission than the native LuxCDABE system under several antibiotic treatments, although these experiments do not establish ATP availability as the causal mechanism.
    Keywords:  autonomous bioluminescence systems; bacterial luciferase; bioimaging; bioluminescence; biosensors; lux
    DOI:  https://doi.org/10.1016/j.isci.2026.118029